SID 2026Abstract 0506Clinical trial
NAV-240, an anti-OX40L/TNFα bispecific antibody, demonstrates biomarker modulation in Phase 1 randomized, double-blind studies of healthy volunteers
Archer C, Smithson G, Chung J, McClintock D, Pupim L, Huh L, Park C, Ha G, Daryani N, Grebe K
SID Annual Meeting 2026Interventional researchChicago, 13–16 May 2026 · published in JID 21 Jul 2026
Topics: Cancer drugs
Abstract
The abstract’s text is on the JID website.
DOI 10.1016/j.jid.2026.06.537 · Not in PubMed: details from Crossref